Pilot Feasibility Trial of Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- Mayo Clinic
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Improvement in serum magnesium levels
研究概览
简要总结
This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In patients who are ill, magnesium is often replaced intravenously (IV) through a vein or by mouth. This study may help researchers find out if being on a magnesium rich diet and using a magnesium lotion on the skin helps to keep magnesium blood levels in an ideal range. This study also investigates side effects and quality of life when receiving different forms of magnesium.
详细描述
PRIMARY OBJECTIVE:
I. Assess if dietary replacement with magnesium rich foods and topical magnesium replacement improves serum magnesium levels in patients with a history of a lymphoproliferative disorder, not on active myelosuppressive chemotherapy, and have a serum magnesium levels 1.5 - 1.9 mg/dL.
SECONDARY OBJECTIVES:
I. Evaluate the compliance of a diet rich in magnesium as well as compliance with topical magnesium replacement in lymphoma patients who have completed therapy and are in remission.
II. Assess feasibility of enrolling patients with a history of lymphoproliferative disorder, not on active treatment with low magnesium levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •PRE-REGISTRATION - INCLUSION CRITERIA:
- •Age >= 18 years
- •Currently have or have had in the past the diagnosis of any type of lymphoma
- •If previously treated, the patient must be off myelosuppressive chemotherapy with no planned chemotherapy for >= 2 months. Patients with lymphoproliferative disorders being observed (i.e., never treated) or those on rituximab (or equivalent) maintenance or chronic oral therapies such as BTK inhibitors, venetoclax, tazemetostat, or corticosteroids are also eligible
- •Able to eat a full range of solid food and liquids and tolerate seeds/nuts
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1, or 2
- •Provide written informed consent
- •Able to recollect dietary intake for the prior 24 hours in order to complete a one-day food record with assistance from a dietitian at each study visit
- •Willing to be seen at the enrolling institution at baseline, and at 4 weeks and 8 weeks (end of treatment) in person or by video/phone
- •Willing to have a blood magnesium checked every 2 weeks x 4 at any Mayo Clinic site
- •Ability to complete questionnaire(s) by themselves or with assistance
- •REGISTRATION - INCLUSION CRITERIA:
- •Magnesium level of 1.5 - 1.9 mg/dL (obtained =< 5 days prior to registration)
排除标准
- •PRE-REGISTRATION - EXCLUSION CRITERIA:
- •Cannot eat normal table food by mouth. NOTE: Patients with any form of feeding tube or a swallowing disorder are not eligible
- •Have taken dedicated magnesium supplements (i.e. magnesium oxide) or intravenous (IV) magnesium =< 28 days prior to pre-registration. Note: If patient is already on a multivitamin containing -magnesium, they may be enrolled, but the brand should not be changed during the 8 weeks on study
- •Co-morbid systemic illnesses such as active infection or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- •Patients with significant gut malabsorptive conditions (such as inflammatory bowel disease or others at the discretion of the investigator) will be excluded as well as patients with chronic kidney disease stage 3b or greater (estimated glomerular filtration rate [eGFR] < 45)
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Receiving any other investigational agent for lymphoma or any other disease
- •Active other malignancy requiring treatment that would interfere with the assessments of this study
- •Major surgery other than diagnostic surgery =< 4 weeks prior to pre-registration
- •Have an allergy to nuts
- •Patients with active skin lymphoma or rashes that would preclude lotion testing
- •Have taken antibiotics =< 7 days prior to pre-registration
研究组 & 干预措施
Cycle 1
Participants consume magnesium rich foods PO daily for 28 days.
干预措施: Quality-of-Life Assessment (Other)
Cycle 1
Participants consume magnesium rich foods PO daily for 28 days.
干预措施: Special Diet Therapy (Behavioral)
Cycle 2, Arm I
Participants continue consuming magnesium rich foods PO daily and apply Ancient Minerals Magnesium Lotion topically daily for 28 days.
干预措施: Magnesium Chloride-based Lotion (Drug)
Cycle 2, Arm I
Participants continue consuming magnesium rich foods PO daily and apply Ancient Minerals Magnesium Lotion topically daily for 28 days.
干预措施: Quality-of-Life Assessment (Other)
Cycle 2, Arm I
Participants continue consuming magnesium rich foods PO daily and apply Ancient Minerals Magnesium Lotion topically daily for 28 days.
干预措施: Special Diet Therapy (Behavioral)
Cycle 2, Arm II
Participants continue consuming magnesium rich foods PO daily for 28 days.
干预措施: Quality-of-Life Assessment (Other)
Cycle 2, Arm II
Participants continue consuming magnesium rich foods PO daily for 28 days.
干预措施: Special Diet Therapy (Behavioral)
结局指标
主要结局
Improvement in serum magnesium levels
时间窗: Baseline up to 2 cycles (56 days)
Will be defined as an increase in magnesium levels of at least 0.2 mg/dL from baseline level or an increase in magnesium level to 2.0 - 2.3 mg/dL at any time after the beginning of replacement.
次要结局
- Feasibility of patient enrollment(Baseline up to 2 cycles (56 days))
- Tolerability and Toxicity Assessment(Up to 56 days)
- Incidence of adverse events(Up to 56 days)
- Patient compliance(Up to 56 days)